Q2 2025 saw 14% sales growth and a 20% rise in adjusted EBITA, driven by strong results in Assistive Tech and MedTech. Specialty Pharma grew slightly and acquired XGX Pharma, while the balance sheet remains robust to support further M&A.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.